Alternol exerts prostate-selective antitumor effects through modulations of the AMPK signaling pathway

Prostate

Volumn 72, Issue 2, 2012, Pages 165-172

  Yeung, Eddie D ^a   Morrison, Alex ^a   Plumeri, Daniel ^a   Wang, Jingying ^a   Tong, Chao ^a   Yan, Xiaoyan ^a,b   Li, Ji ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b TAIYUAN NORMAL UNIVERSITY   (China)

Author keywords

alternol; AMP activated protein kinase; autophagy; Bcl 2; prostate cancer

Indexed keywords

ADENYLATE KINASE; ALTERNOL; ANTINEOPLASTIC AGENT; LC3I PROTEIN; LC3II PROTEIN; PROPIDIUM IODIDE; PROTEIN; PROTEIN BCL 2; PROTEIN P27; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER CELL; CELL CYCLE G2 PHASE; CELL STIMULATION; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAINING; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; AUTOPHAGY; BLOTTING, WESTERN; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG INTERACTIONS; FLOW CYTOMETRY; FORMAZANS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; MALE; PHOSPHORYLATION; PROSTATE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS;

EID: 84455162752     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21417     Document Type: Article

References (33)

1. Penson DF, Chan JM,. Prostate cancer. J Urol 2007; 177 (6): 2020-2029. (Pubitemid 46735946)
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61 (2): 69-90.
3. Albertsen P,. Androgen deprivation in prostate cancer-step by step. N Engl J Med 2009; 360 (24): 2572-2574.
4. Cooperberg MR, Moul JW, Carroll PR,. The changing face of prostate cancer. J Clin Oncol 2005; 23 (32): 8146-8151. (Pubitemid 46211547)
5. Fizazi K, Sternberg CN, Fitzpatrick JM, Watson RW, Tabesh M,. Role of targeted therapy in the treatment of advanced prostate cancer. BJU Int 2010; 105 (6): 748-767.
6. Antonarakis ES, Carducci MA, Eisenberger MA,. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2010; 291 (1): 1-13.
7. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1 (1): 34-45. (Pubitemid 33741879)
8. Liu ZZ, Zhu J, Sun B, Liu S, Geng S, Liu X, Li CL,. Alternol inhibits proliferation and induces apoptosis in mouse lymphocyte leukemia (L1210) cells. Mol Cell Biochem 2007; 306 (1-2): 115-122. (Pubitemid 350001823)
9. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT,. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93 (9): 2325-2327.
10. Liu X, Wang J, Sun B, Zhang Y, Zhu J, Li C,. Cell growth inhibition, G2M cell cycle arrest, and apoptosis induced by the novel compound Alternol in human gastric carcinoma cell line MGC803. Invest New Drugs 2007; 25 (6): 505-517.
11. Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D,. DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: Implications for the androgen receptor functions and regulation. FEBS Lett 2006; 580 (9): 2294-2300. (Pubitemid 43675636)
12. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW,. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994; 54 (10): 2577-2581. (Pubitemid 24173741)
13. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW,. LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis. Prostate 2000; 44 (2): 91-103 Jul 101;144(102). (Pubitemid 30419183)
14. Higuchi M, Kudo T, Suzuki S, Evans TT, Sasaki R, Wada Y, Shirakawa T, Sawyer JR, Gotoh A,. Mitochondrial DNA determines androgen dependence in prostate cancer cell lines. Oncogene 2006; 25 (10): 1437-1445. (Pubitemid 43361929)
15. Zhu Q, Youn H, Tang J, Tawfik O, Dennis K, Terranova PF, Du J, Raynal P, Thrasher JB, Li B,. Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers. Oncogene 2008; 27 (33): 4569-4579.
16. Zhang XY, Li WG, Wu YJ, Bai DC, Liu NF,. Proanthocyanidin from grape seeds enhances doxorubicin-induced antitumor effect and reverses drug resistance in doxorubicin-resistant K562/DOX cells. Can J Physiol Pharmacol 2005; 83 (3): 309-318.
17. Zhang X, Yeung ED, Wang J, Panzhinskiy EE, Tong C, Li W, Li J,. Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells. Clin Exp Pharmacol Physiol 2010; 37 (8): 841-847.
18. Zhao P, Wang J, Ma H, Xiao Y, He L, Tong C, Wang Z, Zheng Q, Dolence EK, Nair S, Ren J, Li J,. A newly synthetic chromium complex-Chromium (d-phenylalanine)(3) activates AMP-activated protein kinase and stimulates glucose transport. Biochem Pharmacol 2009; 77 (6): 1002-1010.
19. Luo Z, Saha AK, Xiang X, Ruderman NB,. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 2005; 26 (2): 69-76. (Pubitemid 40170168)
20. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, Kumar D, Brown ML, Fornace A, Dritschilo A, Collins SP,. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 2009; 8 (4): 733-741.
21. Zhou J, Huang W, Tao R, Ibaragi S, Lan F, Ido Y, Wu X, Alekseyev YO, Lenburg ME, Hu GF, Luo Z,. Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. Oncogene 2009; 28 (18): 1993-2002.
22. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, Slingerland JM, Mills GB,. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 2007; 9 (2): 218-224. (Pubitemid 46420865)
23. Vucicevic L, Misirkic M, Janjetovic K, Vilimanovich U, Sudar E, Isenovic E, Prica M, Harhaji-Trajkovic L, Kravic-Stevovic T, Bumbasirevic V, Trajkovic V,. Compound C induces protective autophagy in cancer cells through AMPK inhibition-independent blockade of Akt/mTOR pathway. Autophagy 2011; 7 (1): 40-50.
24. Wondrak GT,. Redox-directed cancer therapeutics: Molecular mechanisms and opportunities. Antioxid Redox Sign 2009; 11 (12): 3013-3069.
25. Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, Perdona S, Riccardi N, Scagliorini S, Scognamiglio F, Masala D, Ferro M, Palmieri G, Aieta M, Marinelli A, Altieri V, De Placido S, Carteni G,. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int 2011; 107 (2): 234-239.
26. Kumar N,. Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 1981; 256 (20): 10435-10441. (Pubitemid 12219438)
27. Horwitz SB,. Mechanism of action of taxol. Trends Pharmacol Sci 1992; 13 (4): 134-136.
28. Haldar S, Jena N, Croce CM,. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995; 92 (10): 4507-4511.
29. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008; 26 (2): 242-245.
30. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-1512. (Pubitemid 39315317)
31. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH,. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435 (7042): 677-681. (Pubitemid 40825512)
32. Motoshima H, Goldstein BJ, Igata M, Araki E,. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006; 574 (Pt 1): 63-71. (Pubitemid 43905797)
33. White E,. Autophagic cell death unraveled: Pharmacological inhibition of apoptosis and autophagy enables necrosis. Autophagy 2008; 4 (4): 399-401. (Pubitemid 351705133)